

University of Vermont

UVM ScholarWorks

Family Medicine Clerkship Student Projects

Family Medicine Community

2024

Knowledge to Immunity: Guiding Patients on RSV Vaccination

Hosna Mohabbat

University of Vermont

Follow this and additional works at: <https://scholarworks.uvm.edu/fmclerk>



Part of the [Medical Education Commons](#), and the [Primary Care Commons](#)


Recommended Citation

Mohabbat, Hosna, "Knowledge to Immunity: Guiding Patients on RSV Vaccination" (2024). *Family Medicine Clerkship Student Projects*. 1042.

<https://scholarworks.uvm.edu/fmclerk/1042>

This Book is brought to you for free and open access by the Family Medicine Community at UVM ScholarWorks. It has been accepted for inclusion in Family Medicine Clerkship Student Projects by an authorized administrator of UVM ScholarWorks. For more information, please contact schwks@uvm.edu.

Knowledge to Immunity: Guiding Patients on RSV Vaccination



HOSNA MOHABBAT



MOUNTAIN COMMUNITY
HEALTH BRISTOL, VT



SEPTEMBER 2024



DR. BRIAN BATES





Problem Identification & AHEC Focus

AHEC Focus Area - Current Health Issue

RSV vaccination guidelines are more recent recommendation, so patient education has become an important public health concern.

Problem Identification:

RSV vaccines not available on-site at Mountain Community Health

- ✓ Complicates patient access and ability to be educated on-site while receiving vaccination

Patients unsure of who should get RSV vaccine, and why vaccination is important

RSV vaccination is a CDC recommendation that was initiated in 2023 for older adults and high-risk populations after FDA approval of Arexvy and Abrysvo

- ✓ Relatively new subject

Latest recommendation for universal vaccination shifted from adults 60+ to 75+

Public Health Costs & Data

Annual RSV Morbidity and Mortality:

National Level:

177,000 hospitalizations among older adults, 58,000 hospitalizations among kids under 5

14,000 deaths in older adults annually

Vermont Level:

RSV hospitalizations tripled at the UVM Children's Hospital during the 2022

Healthcare Costs of RSV:

RSV-related hospitalizations: \$10,000 - \$15,000/patient

Cost Savings from RSV Vaccination:



RSV vaccine efficacy = **80-90% in reducing severe illness** in adults 60 and older

By preventing hospitalizations, the RSV vaccine significantly **reduces the financial burden** on the healthcare system

Efficacy and Immunity Duration:

RSV vaccines are highly effective (see above) in reducing severe cases of RSV in high-risk populations

Current data suggests that the RSV vaccine provides protection for 6 to 12 months -**research ongoing to determine the need for annual vaccination**



Community Perspective

Many people have **questions** about **who needs the vaccine** and what it protects against

Streamlined solutions necessary to **bridge patient knowledge gap**



Vaccine fatigue exists... we need **clear & concise guidelines** to alleviate confusion for patients AND providers

RSV vaccination is new, so education is key to increasing rates

Intervention and Methodology

Intervention:

- ✓ Created informational material for patients
 - ✓ easy access for patients and providers
 - ✓ outlines RSV vaccine details
 - ✓ Specifies available vaccination sites

Methodology:

- ✓ Distribution and visibility:
 - ✓ during patient visits when discussing immunizations
 - ✓ Pin flyers throughout the clinic for visibility
 - ✓ Bring flyers to community tabling events to increase accessibility
 - ✓ Distribute at clinic tabling events



Response Data

Creation of educational infographic including information about RSV

Categories include:

- What is RSV?
- Symptoms and risks of RSV
- Who should get vaccinated?
- Vaccination sites



Evaluation of Utility and Limitations



Proposed Evaluation



Assess vaccination rates post-distribution




Patient surveys: rate the utility of infographic and gather feedback



Limitations



Literacy levels
Language barriers (not native English speakers)



Address by translating the material in the future
Ensuring comprehension support is available during patient visits

Recommendations for Future Interventions


Create a QR code for
infographic

Allows for increased ease of
distribution

Develop an educational video
Make accessible via QR code
(solution to reading literacy
barrier)

Maintain an updated list of
vaccination sites

As the vaccine becomes more
widely available



References



1. CDC. (2023). RSV Vaccine Recommendations for Adults Aged 60+ and High-Risk Populations.
2. FDA. (2023). Approval of Arexvy and Abrysvo Vaccines for RSV.
3. Blue Cross Blue Shield of Vermont. RSV Hospitalization and Cost Data.
4. Vermont Department of Health. (2022). RSV Hospitalization Trends at University of Vermont Children's Hospital.
5. JAMA. (2023). RSV Vaccine Effectiveness in Reducing Severe Illness in Adults.
6. Nature Reviews. (2023). Duration of Immunity for RSV Vaccines and Annual Vaccination Considerations.
7. CDC. (2024). RSV Vaccination Recommendations for Adults Aged 75 and Older.